Navigation Links
Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy
Date:8/19/2010

ceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy

 

BRUSSELS, August 19, 2010 /PRNewswire/ -- Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.(1)

The prospective, randomised trial compared a protracted infusion of 5-fluorouracil (5FU) chemotherapy to the same chemotherapy in combination with radioembolisation, also known as selective internal radiation therapy (SIRT), using 90Y-resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia). The trial was designed to assess the efficacy and safety of this combination in patients with liver metastases from colorectal cancer and was conducted at three Belgian university hospitals.(2)

The trial recruited 46 patients who had failed all other standard-of-care treatments. The time to the progression of liver metastases - the primary endpoint of the study - increased significantly from a median of 2.1 months in patients receiving 5FU alone to 5.5 months in patients receiving radioembolisation plus 5FU. The risk of progression was 62% lower in patients receiving rad
'/>"/>

SOURCE Sirtex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
3. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Fulton Project Advances to Phase 2 of Loan Guarantee Process
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
10. PRA International Opens Phase I Unit in Budapest
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... , ... Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin ... exclusive License Agreement with Wayne State University to key ... The agreement with Wayne State University grants Arrayit ...
... , OXFORD, ... Appointment Follows Recent Recruitment of Senior Antibody Industry,Leaders and Highlights ... Oxford BioTherapeutics (OBT) has today announced the ... considerable,expertise and experience to OBT at an exciting phase in ...
... Dec. 8 Repligen Corporation (Nasdaq: RGEN ) announced today ... Ph.D., will host a conference call and webcast on Wednesday, December ... Phase 3 clinical trial of RG1068 in MRI imaging of the ... and can be accessed via Repligen,s website at www.repligen.com . ...
Cached Biology Technology:Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4Oxford BioTherapeutics Appoints Michael Moore as Chairman 2Oxford BioTherapeutics Appoints Michael Moore as Chairman 3Oxford BioTherapeutics Appoints Michael Moore as Chairman 4Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3
(Date:7/24/2014)... different species of fish, according to a new ... which tested fish anti-predator behaviour. , Three-spined ... model when exposed to additional noise, whereas no ... Lead author Dr Irene Voellmy of Bristol,s School ... aquatic environments have increased substantially during the last ...
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2
... of Preventive Medicine (ACPM) has launched a web ... medicine the practice of changing health behaviors to ... The document summarizes scientific evidence supporting lifestyle interventions. ... such as definitions, reimbursement trends, related practice patterns, ...
... advent of the Human Genome Project an explosion of data ... demand to fine-tune genomic codes, which list the "ingredients for ... A Rutgers UniversityCamden biochemist is addressing this ... "background checks" on all known enzyme functions. Thanks to ...
... increases in obesity and associated diseases -- and fiery debates ... team has identified a new genetic mechanism that controls the ... to new treatments for obesity and type 2 diabetes, and ... people and dramatically cut health care costs. A research ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2Rutgers-Camden developing enzyme function database 2UCF discovery could open door to obesity, diabetes treatments 2
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
... Agencourt offers SNP loci identification ... includes automated assay design, intensive assay ... sequencing of Corriell or customer-supplied samples ... Discovery service provides for rapid and ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
Biology Products: